In the article by Greenberg et al, entitled “International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes,” which appeared in the March 15, 1997 (Vol 89, No 6, pp 2079-2088) issue, a correction should be noted. In the text p 2080 and in Table 1, neutropenia (absolute neutrophil count, ANC) was inadvertently and incorrectly stated as being defined as <1,500/μL rather than <1,800/μL. The latter number (<1,800/μL) was used to define this cytopenia for the risk scoring indicated in Table 3 and for generating the International Prognostic Scoring System (IPSS) risk groups. As some readers may utilize the number 1,500/μL for their classification of neutropenia, we recalculated the impact of this error on our own data and demonstrated that this change was clinically and statistically insignificant. If this number (1,500/μL) had been used, only 8 patients (of 816 patients, 1%) would have needed reclassification for Survival and 7 (of 759 patients) reclassified for AML evolution. All of the reclassified patients would have been changed from either the Intermediate-2 or -1 categories into the Low-Risk group, as fewer patients would have been defined as being neutropenic. The median survival and AML evolution times and Kaplan-Meier curves were essentially unaltered when using this changed value. Readers should be aware of this correction and use the <1,800/μL cutpoint for categorizing MDS patients according to the IPSS.